Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine

por Kantor, Daniel, Bright, Jeremy R., Burtchell, Jeri
Publicado 2017

Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Patient Education

por Kantor, Daniel, Bright, Jeremy R., Burtchell, Jeri
Publicado 2017

Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression

por Burtchell, Jeri, Fetty, Kristen, Miller, Katelyn, Minden, Kit, Kantor, Daniel
Publicado 2019

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial

por Okuda, Darin T, Kantor, Daniel, Jaros, Mark, deVries, Tina, Hunter, Samuel
Publicado 2022

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study

por Okuda, Darin T, Kantor, Daniel, Jaros, Mark, deVries, Tina, Hunter, Samuel
Publicado 2023

PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions

por Brooks, Benjamin Rix, Crumpacker, David, Fellus, Jonathan, Kantor, Daniel, Kaye, Randall E.
Publicado 2013

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

por Kantor, Daniel, Pham, Timothy, Patterson-Lomba, Oscar, Swallow, Elyse, Dua, Akanksha, Gupte-Singh, Komal
Publicado 2023

Equivalent Gene Expression Profiles between Glatopa(™) and Copaxone(®)

por D’Alessandro, Josephine S., Duffner, Jay, Pradines, Joel, Capila, Ishan, Garofalo, Kevin, Kaundinya, Ganesh, Greenberg, Benjamin M., Kantor, Daniel, Ganguly, Tanmoy C.
Publicado 2015

Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate

por D’Alessandro, Josephine, Garofalo, Kevin, Zhao, Ganlin, Honan, Christopher, Duffner, Jay, Capila, Ishan, Fier, Ian, Kaundinya, Ganesh, Kantor, Daniel, Ganguly, Tanmoy
Publicado 2017

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc anal...

por Calkwood, Jonathan, Cree, Bruce, Crayton, Heidi, Kantor, Daniel, Steingo, Brian, Barbato, Luigi, Hashmonay, Ron, Agashivala, Neetu, McCague, Kevin, Tenenbaum, Nadia, Edwards, Keith
Publicado 2014

Digital Scientific Platform for Independent Content in Neurology: Rigorous Quality Guideline Development and Implementation

por Kantor, Daniel, Farlow, Martin, Ludolph, Albert, Montaner, Joan, Sankar, Raman, Sawyer Jr, Robert N, Stocchi, Fabrizio, Lara, Agnès, Clark, Sarah, Deschet, Karine, Ouyahia, Loucif, Hadjiat, Yacine
Publicado 2022

Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis

por Bell, Christine, Anderson, James, Ganguly, Tanmoy, Prescott, James, Capila, Ishan, Lansing, Jonathan C., Sachleben, Richard, Iyer, Mani, Fier, Ian, Roach, James, Storey, Kristina, Miller, Paul, Hall, Steven, Kantor, Daniel, Greenberg, Benjamin M., Nair, Kavita, Glajch, Joseph
Publicado 2017

Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of th...

por Hunter, Samuel F., Aburashed, Rany A., Alroughani, Raed, Chan, Andrew, Dive, Dominique, Eichau, Sara, Kantor, Daniel, Kim, Ho Jin, Lycke, Jan, Macdonell, Richard A. L., Pozzilli, Carlo, Scott, Thomas, Sharrack, Basil, Wiendl, Heinz, Chung, Luke, Daizadeh, Nadia, Baker, Darren P., Vermersch, Patrick
Publicado 2021